Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.
Nguyen
Vu H
VH
Lawrence
H Jeffrey
HJ
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000588:Amines; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced* / Q000517:prevention & control*; D003509:Cyclohexanecarboxylic Acids; D000077143:Docetaxel; D000077206:Gabapentin; D006801:Humans; D018482:Muscle, Skeletal / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000700:Analgesics; D000972:Antineoplastic Agents, Phytogenic; D003509:Cyclohexanecarboxylic Acids; D043823:Taxoids; D000077143:Docetaxel; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D017239:Paclitaxel